Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (175,850)	$ (38,988)	$ (24,067)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,987	1,958	1,964
Accretion of premium/discount on marketable securities	(4,895)	0	0
Noncash lease expense	444	321	290
Stock-based compensation expense	99,958	5,945	2,530
Change in fair value of stock warrants	0	182	(30)
Change in fair value of contingent consideration	3,242	2,714	(712)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	(750)	(837)	113
Accounts payable	5,672	1,372	(1,477)
Accrued compensation	1,641	1,460	947
Accrued clinical trial site costs	(1,567)	171	(198)
Operating lease liabilities	(183)	(309)	(302)
Other liabilities	1,205	1,071	161
Net cash used in operating activities	(69,096)	(24,940)	(20,781)
Cash flows from investing activities:
Purchases of property and equipment	(218)	0	(13)
Purchases of marketable securities	(356,464)	0	0
Maturities of marketable securities	131,000	0	0
Net cash used in investing activities	(225,682)	0	(13)
Cash flows from financing activities:
Proceeds from issuance of debt, net of issuance costs	49,888	0	0
Proceeds from the sale of common stock, net of issuance costs	148,955	0	0
Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs	0	137,857	14,108
Proceeds from exercise of common stock and pre-funded stock warrants	12,866	41,815	0
Proceeds from exercise of stock options	1,316	347	0
Tax withholding payments for net share-settled equity awards	0	0	(16)
Net cash provided by financing activities	213,025	180,019	14,092
Net increase (decrease) in cash and cash equivalents	(81,753)	155,079	(6,702)
Cash and cash equivalents, beginning of period	169,681	14,602	21,304
Cash and cash equivalents, end of period	87,928	169,681	14,602
Supplemental disclosure of non-cash operating and financing information
Operating lease right-of-use assets obtained in exchange for operating lease obligations	2,835	597	0
Non-cash exercise of 2018 PIPE Warrants	0	183	0
Purchases of property and equipment included in accounts payable	1	0	0
Debt issuance costs included in accounts payable	$ 62	$ 0	$ 0